US BioTec Inc

PINK:USBC USA Agricultural Inputs
Market Cap
$0.91
Market Cap Rank
#51288 Global
#15990 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$2.50
About

US BioTec, Inc. engages in the development, manufacture, marketing, and distribution of bio-degradable, nontoxic, and noncarcinogenic products in the United States. Its product portfolio consists of approximately 30 products, which stimulate plants that produce crops; correct microbial and mineral problems present in soils; and rehabilitate the soil ecosystem by breaking down the residual build-u… Read more

US BioTec Inc (USBC) - Net Assets

Latest net assets as of March 2005: $351.38K USD

Based on the latest financial reports, US BioTec Inc (USBC) has net assets worth $351.38K USD as of March 2005.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($939.54K) and total liabilities ($588.16K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $351.38K
% of Total Assets 37.4%
Annual Growth Rate 101.59%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 185.59

US BioTec Inc - Net Assets Trend (2003–2005)

This chart illustrates how US BioTec Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for US BioTec Inc (2003–2005)

The table below shows the annual net assets of US BioTec Inc from 2003 to 2005.

Year Net Assets Change
2005-12-31 $172.91K -11.51%
2004-12-31 $195.40K +359.67%
2003-12-31 $42.51K --

Equity Component Analysis

This analysis shows how different components contribute to US BioTec Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1204.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2005)

Component Amount Percentage
Common Stock $642.39K 371.51%
Total Equity $172.91K 100.00%

US BioTec Inc Competitors by Market Cap

The table below lists competitors of US BioTec Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in US BioTec Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2004 to 2005, total equity changed from 195,402 to 172,915, a change of -22,487 (-11.5%).
  • Net loss of 376,315 reduced equity.
  • Other factors increased equity by 353,828.

Equity Change Factors (2004 to 2005)

Factor Impact Contribution
Net Income $-376.31K -217.63%
Other Changes $353.83K +204.63%
Total Change $- -11.51%

Book Value vs Market Value Analysis

This analysis compares US BioTec Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.00x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-12-31 $0.00 $0.00 x
2004-12-31 $0.00 $0.00 x
2005-12-31 $0.42 $0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently US BioTec Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -217.63%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -23.01%
  • • Asset Turnover: 1.83x
  • • Equity Multiplier: 5.17x
  • Recent ROE (-217.63%) is below the historical average (-149.31%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 -182.63% -5.66% 1.88x 17.13x $-81.88K
2004 -47.68% -7.29% 1.52x 4.30x $-112.70K
2005 -217.63% -23.01% 1.83x 5.17x $-393.61K

Industry Comparison

This section compares US BioTec Inc's net assets metrics with peer companies in the Agricultural Inputs industry.

Industry Context

  • Industry: Agricultural Inputs
  • Average net assets among peers: $1,234,454,915
  • Average return on equity (ROE) among peers: -88.72%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
US BioTec Inc (USBC) $351.38K -182.63% 1.67x $0.96
Argo Living Soils Corp (ARLSF) $117.11K -241.15% 0.57x $4.77 Million
American Vanguard Corporation (AVD) $282.36 Million 4.53% 0.52x $93.02 Million
Bee Vectoring Technologies International Inc (BEVVF) $1.82 Million -170.52% 0.16x $47.51K
Benson Hill, Inc. Common Stock (BHIL) $86.04 Million -134.02% 2.19x $178.85K
BHILW (BHILW) $86.04 Million -134.02% 2.19x $286.16K
Bioceres Crop Solutions Corp (BIOX) $351.38 Million 0.92% 1.43x $16.37 Million
CO2 Gro Inc (BLONF) $577.93K -224.34% 1.65x $154.65K
China BlueChemical Ltd (CBLUF) $7.05 Billion 23.77% 0.29x $484.41 Million
CF Industries Holdings Inc (CF) $4.39 Billion 15.96% 1.90x $15.33 Billion
China Green Agriculture Inc (CGA) $100.10 Million -28.38% 0.63x $14.93 Million